Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass

Summary

This is a multiple site, proof of concept feasibility study to describe the effect of GTx-024 9 or 18 mg on physical function in female subjects, from protocol G200802, with ER+/AR+ breast cancer.

Timeline

Start

2016-04

Primary completion

2018-02

Completion

2018-02

Outcome

Outcome not reported

Stopped: “Investigational drug development was halted.”

Drugs

Indications